ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.5%

ProMIS Neurosciences, Inc. (NASDAQ:PMN)’s share price rose 1.5% during mid-day trading on Friday . The company traded as high as $1.98 and last traded at $1.98. Approximately 1,032 shares changed hands during trading, a decline of 97% from the average daily volume of 37,766 shares. The stock had previously closed at $1.95.

ProMIS Neurosciences Trading Up 1.5 %

The firm’s 50-day moving average price is $2.04 and its 200 day moving average price is $1.78. The company has a market capitalization of $37.54 million, a price-to-earnings ratio of -1.75 and a beta of 0.67.

ProMIS Neurosciences (NASDAQ:PMN) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that ProMIS Neurosciences, Inc. will post -1.11 earnings per share for the current fiscal year.

Institutional Trading of ProMIS Neurosciences

An institutional investor recently bought a new position in ProMIS Neurosciences stock. Affinity Asset Advisors LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 265,958 shares of the company’s stock, valued at approximately $527,000. Affinity Asset Advisors LLC owned approximately 3.10% of ProMIS Neurosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 50.13% of the company’s stock.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.